Article

Living and dying on her own terms

Author(s):

On Easter Sunday, The New York Times ran a story about a palliative care physician in New York City who died of breast cancer. More than just another "she fought to live" story, the life of Dr. Desiree Pardi presented a vivid picture of the complicated internal conflict of cancer patients. The story spotlighted both the individuality of each person in the way he or she chooses to live and die, and the challenges of health care professionals in caring for such diversity of thought. What makes Dr. Pardi's story a study in dichotomy is that she chose to specialize in palliative care in part because of her own struggle with breast cancer after being diagnosed at age 31. She felt patients should accept the inevitable and the pain management that goes with it as they approached the end of their lives. Then she faced a recurrence of her cancer, and the inevitable became something she refused to accept. She wanted to know as little about her cancer as possible, asking that her husband be the one to get the information; she also chose the most aggressive treatment in every case, hoping to find the magic bullet that would extend her life. The result was a life that ended in uncontrolled pain and unresolved issues. Her husband didn't get to say goodbye.But what I have found most interesting about this piece is the number of comments it has garnered in less than a day--more than 450 the last time I looked. Some people lauded her for taking her life into her own hands and ending it on her own terms. Others lamented that she didn't use the gifts of her palliative care training. Still others looked at her wealth and the ability to pay out of pocket for expensive treatment that may have worked.It's a story where no one is right or wrong, and nothing is black or white--just like life and death.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content